Kartik Padh

Director of the BOD; President

With over 20 years of international experience in the biopharma industry in Asia-Pacific, Europe and USA, Mr. Padh has held multiple management and leadership positions in Quality and Compliance, Operations and Technology Transfer, Validation and Automation. He was previously Head of Quality / Head of Manufacturing at MSD Singapore; as Head of Manufacturing Quality at Samsung Biologics, helping to gain successful licensure of two DS and two DP facilities; and various technical and management positions in the industry including in Genentech.

Donald Palahnuk

Director of the BOD; CTO

With over 30 years of biotech experience, Mr. Palahnuk has demonstrated high-level leadership in process development, MST, technology transfer, and technical operations oversight. He founded and led MST or PD departments at Samsung Biologics, TopAlliance, ImClone/Eli Lilly, and Bio-Thera, where he managed TT and supported registration for ipilimumab, rituximab, nivolumab, and several other novel therapeutics. He also held engineering positions at global companies including Hoffmann-La Roche, Procter and Gamble, and Takeda. He has an M.S. in Chemical Engineering from Lehigh University.

John Zhang, PhD

COO

With over 25 years of experience in both academia and the biotech industry, Dr. Zhang was previously Head & VP Biologics CMC at Zai Lab; VP Process Development & Manufacturing Technology at BeiGene; SVP Biopharmaceuticals and Director of Biopharmaceutical Research Institute at Qilu; Senior Researcher and Director of Biologics Process Validation Laboratory in MSAT, Lonza Biologics. He holds a PhD in Cellular and Molecular Biology from Eastern Virginia Medical School & Old Dominion University.

George Siu

VP Quality and Compliance

With over 20 years of biotech and pharmaceutical experience, Mr. Siu has held leading positions in Quality Assurance and Quality Control at Baxter Biosciences, Amgen, and Samsung Biologics. He has lead teams in Quality Assurance, including: Quality Digital Transformation, Data Integrity, Quality Management Systems, and Quality Control. He has a proven track record in implementing industry leading and enhanced digital Quality systems and processes.

Jinliang Song

VP Procurement

Mr. Song boasts a distinguished career, having held key management positions in prominent steel companies, including Tangshan Ganglu Iron & Steel Co., Ltd., one of northern China’s largest steel enterprises based in Tangshan. In 2002, he co-founded Hebei Zhonggang Steel and Iron Co., Ltd in Yutian, China, where he served as the Chief Financial Officer. Mr. Song has held many executive management positions in large steel companies including one of the largest in Northern China, Tangshan Ganglu Iron & Steel Co., Ltd. He is also the co-founder and CFO of Hebei Zhonggang Steel and Iron Co., Ltd in Yutian, China, which achieved annual sales revenue over $400 million in 2009 and was awarded “The City’s Most Outstanding Enterprise,” “Green Enterprise,” and “Enterprise of Honor.”

Concurrently, Mr. Song strategically transitioned into the real estate sector, undertaking deliberate acquisitions of expansive land parcels and development rights in rural, undeveloped areas. A notable investment involved the majority development rights acquisition of Xiangyun Island, located on the Hebei province coastline, approximately a 3-hour drive from Beijing. This pivotal development right was subsequently integrated into Cheerland Investment Group, an entity co-founded by Mr. Song in 2005.

In 2008, Mr. Song played a crucial role in co-founding Langfang Shangcheng Real Estate Development Co., Ltd, directing its focus towards large-scale urban development projects in Langfang city, a thriving satellite town of Beijing, China. Under his leadership, the company successfully realized the development of an over 15 million square foot mixed-use complex, encompassing shopping centers, residential buildings, offices, and hospitality spaces. Mr. Song also spearheaded the acquisition of the Riverfront Garden Project in Shanghai, breaking ground in September 2013.

In that same transformative year of 2013, Mr. Song actively expanded Cheerland Investment Group’s real estate network to Los Angeles, New York, and other major U.S. real estate markets. Simultaneously, he led Langfang Shangcheng in making strides in the U.S. real estate market with a housing development project in North Dakota.

Mr. Song earned his junior college degree in construction from Xi’an Jiaotong University (Tangshan Campus). He pursued further studies in accounting and finance through Hunan University’s continuing education program. Mr. Song’s dedication to professional development is underscored by his qualification as a medium-level accountant in China, showcasing his expertise and proficiency in the financial domain.

Mark Ramsey

VP, CLB Shanghai

Over 20 years of experience in the Biotech industry, working in areas of large-scale mammalian production (Amgen) to small batch process of vaccines (Novartis, Flu and Emergent BioSolutions, Anthrax).  Most recently he has worked for KBI BioPharma, ThermoFisher Biotech, and Samsung Biologics.  He has experience in Manufacturing (Upstream and Downstream), Quality (Investigations), Process Engineering, MSAT Technical Transfer (Upstream and Downstream), and Process Validation.  Mark received his B.S. degree in Chemical Engineering from the University of Missouri at Columbia.

Yih Horng Tan, PhD

VP Drug Product

Dr. Tan has extensive experiences in running large domestic and international technology transfer projects. He was previously Senior Manager of Drug Product Manufacturing Science and Technology at the BrammerBio part of Thermo Fisher Scientific; Senior Process Engineer at Lantheus Medical Imaging; Senior Research Scientist at Albany Molecular Research. He holds a B.S. in Chemistry from Acadia University, Ph.D. in Chemical Biology from University of California, Davis, and completed post-doctoral training at University of Missouri, St. Louis.

Tim Wu, PhD

CSO & China BD Head

With 26 years of experience in biologics development, Dr. Wu worked in the US at Boehringer Ingelheim, Pfizer, Merck (MSD), Emory University, among others, where he directed & contributed as a core member for three antibody drugs approved & marketed in the US, Europe, and Japan. Since 2016 he has held drug development leadership positions in China at GSK, Janssen, Transcenta, China Resources Biopharma, among others. He holds BS & MS degrees in Medicine from Wuhan University, and PhD from University of Hong Kong.

Tim Calvert, PhD

VP International Markets

Dr. Calvert has more than 15 years of experience in leading delivery of integrated drug discovery & development solutions from virtual startups to global pharma, in both small and large molecule modalities. With a proven record of leadership and accomplishment, he was General Manager, Material and Structural Analysis at Thermo Fisher Scientific; VP at Abzena and Concept Life Sciences; Business Development Account Director at Catalent; and launched Lonza’s cell and gene therapy business in E.U. markets. He obtained his Ph.D. in Biotechnology from Glasgow Caledonian University.

Harvey He, MBA

VP, CLB Shenzhen

With over 26 years of experience in the pharma and biotech industry, Mr. He has held senior management positions in various companies such as Pharmaron Biologics, WuXi Biologics, Fosun Pharma, Thermo Fisher Scientific and Abcam, in the US, Canada and China. Familiar with GMP regulations in China, Europe and the US, as well as quality systems. He holds a B.S. degree in microbiology from Shandong University and MBA from the University of Alabama.

Rick von Moos

VP Facilities Engineering

Over 25 years dedicated to global GMP bio-manufacturing startups and operation experience. Previously he was Lead Engineer (Quality technology group) at Samsung Biologics; Sr. Supervisor of production maintenance at Genentech/ Roche drug product facility; Clean Utilities start up lead at a number of Genentech facilities (CCP1, CCP2) and Porrino Spain.

Stephen Joshua Hee

Sr. Director QAS

With 20 years of experience in the biopharma industry, Mr. Hee has led various quality teams in Quality Control, Quality Validation, Quality Operations, External Quality, and Quality Systems to meet both quality and business requirements for companies like GSK Vaccine, Abbott, MSD Biotech, Lonza, Clover Biopharmaceuticals (Vaccine) and Thermofisher Scientific. He holds an Executive Master’s in Leadership, Strategy and Innovation, and a B.Sc degree in Biomedical Science and Molecular Biology from Murdoch University, AUS.

Fermin Valdon

Sr. Director Quality Engineering

With more than 15 years of pharmaceutical experience in cGMP manufacturing environment, Mr. Valdon previously spent 6 years at Samsung Biologics providing validation oversight in all aspects of New Product Introduction including cleaning validation, equipment qualification, process validation, exception and deviation investigations and change controls. He also supported preparation of Common Technical Document for health agency inspections for DS and DP marketing approvals for US, EU and rest of the world markets.

Joe Zhou

Sr. Director Regulatory Affairs

With more than 15 years of experience in quality and registration work in the pharmaceutical industry, Mr. Zhou has served as Director of Regulatory Affairs at Hepalink Pharmaceutical; Director of Global Business and Regulatory at GeneScience Pharmaceutical; Deputy GM of Regulatory Affairs at Fosun Pharma. He has led filing and marketing of multiple products, obtaining multiple IND, BLA, ANDA approvals from China, the United States, and the European Union.

Zhiyou Pan, PhD

Director MSAT Upstream

With 10 years of experience in biopharmaceutical process development and technology transfer, Dr. Pan has served as Process Supervisor, Process Manager, and Deputy Director of R&D at Guangdong Temple Biochemical, Guangzhou Beixiu Biotech, Shenzhen Kexing Pharmaceutical, and Guangdong Hengda Pharmaceutical. He holds a PhD in Fermentation Engineering from South China University of Technology.

Yailen Rivero Barreiro

Director Clinical Manufacturing

Over 18 years of experience in manufacturing of recombinant proteins for therapeutic use from mammalian cell culture, with leadership position in manufacturing. Experience in scale up, process analysis and validation of upstream and downstream process and Common Technical Document (CTD). Previously she was Production Director at Biotech Pharmaceutical (Beijing, P.R. China), and Director of Drug Substance Operations at the Molecular Immunology Center (Cuba).